RedHill Biopharma Ltd. logo
RedHill Biopharma Ltd. RDHL
$ 6.7 3.63%

Annual report 2023
added 11-09-2024

report update icon

RedHill Biopharma Ltd. Balance Sheet 2011-2024 | RDHL

Annual Balance Sheet RedHill Biopharma Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- 53.8 M -25.2 M - - -53.8 M -5.99 M -5.89 M -11.9 M -16.8 M -14.1 M

Long Term Debt

- - - 81.4 M 2.98 M - - - - - - - -

Long Term Debt Current

718 K 1.03 M 1.62 M 1.71 M 834 K - - - - - - - -

Total Non Current Liabilities

- - - - 3.48 M 844 K 448 K 6.16 M 1.24 M 2.12 M - - 886 K

Total Current Liabilities

- - - - - - - - - - - - -

Total Liabilities

21 M 207 M 172 M 166 M 14.1 M 11.2 M 12.3 M 11.5 M 6.75 M 3.84 M 2.42 M 1.08 M 1.4 M

Deferred Revenue

- - - 19.5 M - - - - - - - - -

Retained Earnings

- - - -280 M -208 M -169 M -133 M -88.6 M -60.9 M -42.2 M -33.3 M -23.9 M -15.2 M

Total Assets

23 M 159 M 181 M 180 M 74.1 M 62.4 M 57.3 M 74.2 M 66.8 M 28.9 M 14.3 M 20.1 M 20.2 M

Cash and Cash Equivalents

5.57 M 20 M 29.5 M 29.3 M 29 M 29 M 16.5 M 53.8 M 21.5 M - - - -

Book Value

2.07 M -48.4 M 8.88 M 13.9 M 60 M 51.2 M 45.1 M 62.7 M 60.1 M 25 M 11.9 M 19 M 18.8 M

Total Shareholders Equity

- - - 13.9 M 60 M 51.2 M 45.1 M 62.7 M 60.1 M - - - -

All numbers in USD currency

Quarterly Balance Sheet RedHill Biopharma Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 2.57 M - 2.98 M - 3.81 M - 4.04 M - 2.98 M - 3.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 90.8 M - 94.9 M - 93.1 M - 95.9 M - 3.48 M - 3.74 M - 844 K - - - 448 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 172 M - 174 M - 166 M - 132 M - 14.1 M - 17.8 M - 11.2 M - 11.9 M - 12.3 M - - - 11.5 M - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -368 M - -326 M - -280 M - -240 M - -208 M - -188 M - -169 M - -152 M - -133 M - - - -89.6 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 181 M - 204 M - 180 M - 166 M - 74.1 M - 49.7 M - 62.4 M - 37.8 M - 57.3 M - - - 74.2 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 29.5 M - 51.8 M 76 M 29.3 M - 22.3 M 81.6 M 29 M - 9 M 23 M 29 M - 5.56 M 7.56 M 16.5 M - 15.3 M 29.6 M 53.8 M - - - 21.5 M - - - 5.89 M - - - - - - - - - - - - - - -

Book Value

- - - - 8.88 M - 29.6 M - 13.9 M - 34.6 M - 60 M - 31.9 M - 51.2 M - 25.9 M - 45.1 M - - - 62.7 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 8.88 M - 29.6 M 53 M 13.9 M - 34.6 M 43.6 M 60 M - 31.9 M 41.9 M 51.2 M - 25.9 M 36.3 M 45.1 M - 48.8 M 58.9 M 62.7 M - - - 60.1 M - - - 25 M - - - - - - - - - - - - - - -

All numbers in USD currency